Tags

Type your tag names separated by a space and hit enter

Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
Curr Pharm Biotechnol 2017; 18(12):945-963CP

Abstract

BACKGROUND

Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored.

METHODS

Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)- 12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).

RESULTS

In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and safety of TNFα inhibitors largely used in the management of the cutaneous disease.

CONCLUSION

Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed anti-TNFα are here discussed in detail.

Authors+Show Affiliations

Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29424306

Citation

Campanati, Anna, et al. "Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- Α Inhibitors." Current Pharmaceutical Biotechnology, vol. 18, no. 12, 2017, pp. 945-963.
Campanati A, Molinelli E, Brisigotti V, et al. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors. Curr Pharm Biotechnol. 2017;18(12):945-963.
Campanati, A., Molinelli, E., Brisigotti, V., & Offidani, A. (2017). Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors. Current Pharmaceutical Biotechnology, 18(12), pp. 945-963. doi:10.2174/1389201019666180209121804.
Campanati A, et al. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- Α Inhibitors. Curr Pharm Biotechnol. 2017;18(12):945-963. PubMed PMID: 29424306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors. AU - Campanati,Anna, AU - Molinelli,Elisa, AU - Brisigotti,Valerio, AU - Offidani,Annamaria, PY - 2017/03/20/received PY - 2017/08/17/revised PY - 2017/10/23/accepted PY - 2018/2/10/pubmed PY - 2018/7/3/medline PY - 2018/2/10/entrez KW - Adalimumab KW - anti-TNFα KW - certolizumab pegol KW - efficacy KW - etanercept KW - golimumab KW - infliximab KW - safety SP - 945 EP - 963 JF - Current pharmaceutical biotechnology JO - Curr Pharm Biotechnol VL - 18 IS - 12 N2 - BACKGROUND: Psoriasis is a chronic immune-mediated inflammatory disorder, with an estimated global prevalence of 2-3%. Psoriasis is associated with an impaired health-related quality of life and a substantial economic burden. Biologics, which target the pathways involved in the pathogenesis of psoriasis, represent an established therapeutic approach for moderate-to-severe plaque psoriasis, with remarkable efficacy and safety profile extensively examined and monitored. METHODS: Biological therapies currently available can be divided into three main categories: the TNFα antagonists (infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), the interleukin (IL)- 12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab). RESULTS: In this section, we explore the complex role of TNFα in psoriasis as well as the efficacy and safety of TNFα inhibitors largely used in the management of the cutaneous disease. CONCLUSION: Dosing regimens, administration, pharmacodynamics profiles, efficacy, and safety of licensed anti-TNFα are here discussed in detail. SN - 1873-4316 UR - https://www.unboundmedicine.com/medline/citation/29424306/Biologic_Therapy_in_Psoriasis__Part_I_:_Efficacy_and_Safety_of_Tumor_Necrosis_Factor__α_Inhibitors_ L2 - http://www.eurekaselect.com/159670/article DB - PRIME DP - Unbound Medicine ER -